Bibliographic Details
| Title: |
Assessing the contribution of rare protein-coding germline variants to prostate cancer risk and severity in 37,184 cases. |
| Authors: |
Mitchell, Jonathan, Camacho, Niedzica, Shea, Patrick, Stopsack, Konrad H., Joseph, Vijai, Burren, Oliver S., Dhindsa, Ryan S., Nag, Abhishek, Berchuck, Jacob E., O'Neill, Amanda, Abbasi, Ali, Zoghbi, Anthony W., Alegre-Díaz, Jesus, Kuri-Morales, Pablo, Berumen, Jaime, Tapia-Conyer, Roberto, Emberson, Jonathan, Torres, Jason M., Collins, Rory, Wang, Quanli |
| Source: |
Nature Communications; 2/18/2025, Vol. 16 Issue 1, p1-11, 11p |
| Subject Terms: |
WHOLE genome sequencing, GENETIC variation, DISEASE risk factors, LIFE sciences, MISSENSE mutation |
| Abstract: |
To assess the contribution of rare coding germline genetic variants to prostate cancer risk and severity, we perform here a meta-analysis of 37,184 prostate cancer cases and 331,329 male controls from five cohorts with germline whole exome or genome sequencing data, and one cohort with imputed array data. At the gene level, our case-control collapsing analysis confirms associations between rare damaging variants in four genes and increased prostate cancer risk: SAMHD1, BRCA2 and ATM at the study-wide significance level (P < 1×10−8), and CHEK2 at the suggestive threshold (P < 2.6×10−6). Our case-only analysis, reveals that rare damaging variants in AOX1 are associated with more aggressive disease (OR = 2.60 [1.75–3.83], P = 1.35×10−6), as well as confirming the role of BRCA2 in determining disease severity. At the single-variant level, our study reveals that a rare missense variant in TERT is associated with substantially reduced prostate cancer risk (OR = 0.13 [0.07–0.25], P = 4.67×10−10), and confirms rare non-synonymous variants in a further three genes associated with reduced risk (ANO7, SPDL1, AR) and in three with increased risk (HOXB13, CHEK2, BIK). Altogether, this work provides deeper insights into the genetic architecture and biological basis of prostate cancer risk and severity, with potential implications for clinical risk prediction and therapeutic strategies. By bringing together whole exome and genome sequencing data from five cohorts, the authors assess the contribution of rare germline variants to prostate cancer risk and severity, further validating previously reported genes, and implicating a role for genes not previously reported. Peer review information Nature Communications thanks the anonymous reviewer(s) for their contribution to the peer review of this work. A peer review file is available. [ABSTRACT FROM AUTHOR] |
|
Copyright of Nature Communications is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
